HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis.

AbstractPURPOSE:
Non-infectious uveitis associated with Vogt-Koyanagi-Harada (VKH) disease or sarcoidosis is commonly treated with systemic corticosteroids (SCS). We assessed the use of SCS for non-infectious uveitis relapses in Japanese clinical practice.
STUDY DESIGN:
Multicenter, retrospective chart review (UMIN Clinical Trial Registry; UMIN000032390).
METHODS:
One hundred fifty-seven patients (15- ≤ 75 years; 103 VKH disease, 54 sarcoidosis) given SCS to treat a relapse of non-infectious intermediate, posterior, or panuveitis accompanying VKH disease or sarcoidosis were studied (August 2011-December 2018). SCS dose and duration, concomitant medications, subsequent relapses, and steroid-related adverse drug reactions (ADRs) were analyzed for 12 months after target relapse treatment. Relationships between background factors and total SCS dose were analyzed (logistic regression).
RESULTS:
Mean (± SD) total SCS dose over 12 months after target relapse treatment was 3874 ± 2775 mg, and was higher in patients with immunosuppressants than in those without (4575 mg vs 3496 mg). Immunosuppressant use was the only factor significantly associated with higher total SCS dose (p = 0.0196). Mean duration of SCS treatment for relapse was 318.7 ± 89.3 days. Only 29.3% of patients were steroid-free after 12 months; the percentage was higher in patients without immunosuppressants (36.3% vs 16.4%). Subsequent relapse was experienced by 39.5% of patients, and 13.4% had a steroid-related ADR (mostly glaucoma or diabetes).
CONCLUSION:
In Japanese clinical practice, many patients with recurrent uveitis accompanying VKH disease or sarcoidosis received SCS for relapse for ≥ 300 days, suggesting that reducing corticosteroids is challenging in patients with difficulty suppressing inflammation.
AuthorsKenichi Namba, Hiroshi Takase, Yoshihiko Usui, Fumihiko Nitta, Kazuichi Maruyama, Sentaro Kusuhara, Masaki Takeuchi, Atsushi Azumi, Ryoji Yanai, Yutaka Kaneko, Eiichi Hasegawa, Kei Nakai, Hidekazu Tsuruga, Kazuo Morita, Toshikatsu Kaburaki
JournalJapanese journal of ophthalmology (Jpn J Ophthalmol) Vol. 66 Issue 2 Pg. 130-141 (Mar 2022) ISSN: 1613-2246 [Electronic] Japan
PMID35044561 (Publication Type: Journal Article, Multicenter Study, Observational Study)
Copyright© 2022. Japanese Ophthalmological Society.
Topics
  • Humans
  • Recurrence
  • Retrospective Studies
  • Sarcoidosis (complications, diagnosis, drug therapy)
  • Uveitis (complications, diagnosis, drug therapy)
  • Uveomeningoencephalitic Syndrome (complications, diagnosis, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: